// App-Quantinova.ai

TCTAP A-140 : Impact of Everolimus-Eluting Stent Length on Outcomes of Percutaneous Coronary Intervention

Researchers

Presenter

  • Hideki Yano

Principal Investigators

  • N/A

Medical Centers

  • Osaka Rousai Hospital, Osaka, Japan

Locations

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • Endocrine/metabolic Diseases (ME)

Disease

  • Chronic kidney disease

  • Coronary Artery Disease

  • Renal disease

  • Venous thrombosis

  • Diabetes

Biomarkers

  • N/A

Drug/Treatment

  • Everolimus

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved